Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003, YH001 and Pembrolizumab in Advanced Solid Tumors
NCT05176509Phase 1Completed
- Sponsor
- Eucure Biopharma
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ciltistotug and YH001 in solid tumor, sponsored by Eucure Biopharma. Primary endpoints: Adverse events (AEs), Maximum Tolerated Dose and 1 more. Started Apr 2022; status: completed.
02
Drugs
ciltistotugYH001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05176509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05176509.